Kymera Therapeutics, Inc. (KYMR) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Biotech momentum with near‑term event: KYMR is up ~28% over 21 days with notable institutional accumulation (Baker Brothers, Rock Springs) and has its FY2025 results/earnings call on 2026‑02‑26; strong cash runway into 2028–2029 and positive early biomarker data support a speculative upside move if management reinforces timelines and clinical strategy.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Heavy Losses • Rich Valuation KYMR has an exceptionally strong balance sheet and liquidity position, but persistent deep losses, negative cash flow, and rich sales/book valuations keep the investment case high-risk.
Price Behavior
Key Price Behavior Insights: • Lower highs • Support rebound • Heavy resistance Support Level: $71.29 Resistance Level: $78.5-$81.7 KYMR has shifted into a clear short-term downtrend over the last month, with support near $71.29 but key resistance still clustered at $78.5-$81.7.
Sentiment & News
Key News Insights: • KT-621 Data • Investor Outreach • Governance Risk Kymera Therapeutics paired encouraging KT-621 clinical updates and steady investor outreach with a shareholder fiduciary-duty investigation, creating a mixed near-term outlook.
AI Summary
KYMR has shifted from a financing-risk story to a well-capitalized, long-runway platform story, but the stock now depends on KT-621/KT-579 delivering differentiated clinical data before its rich valuation and the long 2027 catalyst gap erode investor patience.
Description
Kymera Therapeutics develops small-molecule drugs that induce selective removal of disease-causing proteins by engaging the body’s native protein degradation pathways. Its pipeline includes an IRAK4 candidate in Phase I for several immuno-inflammatory conditions and programs targeting MYD88-mutant lymphoma, STAT3-related hematologic and solid tumors as well as autoimmune and fibrotic diseases, and MDM2-driven malignancies. The company was incorporated in 2015 and is based in Watertown, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 25 | Mar 4 | KYMR | Kymera Therapeutics, Inc. | Biotech momentum with near‑term event: KYMR is up ~28% over 21 days with notable institutional accumulation (Baker Brothers, Rock Springs) and has its FY2025 results/earnings call on 2026‑02‑26; strong cash runway into 2028–2029 and positive early biomarker data support a speculative upside move if management reinforces timelines and clinical strategy. | Closed | -5.0% |